5-Aminomethylquinoxaline-2,3-diones, Part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 5, 1998, Pages 493-498

  Acklin, Pierre ^a   Allgeier, Hans ^a   Auberson, Yves P ^a   Bischoff, Serge ^a   Ofner, Silvio ^a   Sauer, Dirk ^a   Schmutz, Markus ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 QUINOXALINEDIONE DERIVATIVE; 5 AMINOMETHYLQUINOXALINE 2,3 DIONE; AROMATIC AMIDE; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR; GLYCINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SYNTHESIS; MOUSE; NONHUMAN; RECEPTOR AFFINITY;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; MICE; QUINOXALINES; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032478159     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00055-9     Document Type: Article

References (24)

1. 1 a) Leeson, P. D. In Drug Design for Neuroscience; Kozikowski A. P., Ed.; Raven Press Ltd.: New York, 1993; pp. 339-381;
2. b) Lynch, D. R.; Anegawa, N. J.; Verdoorn, T.; Pritchett, D. B. Mol. Pharmacol. 1994, 45, 540-545;
3. c) Herrling, P. L. In The NMDA Receptor, Collingridge, G. L.; Watkins, J. C. Eds.; Oxford University Press: New York, Second Ed. 1994, pp 376-394.
4. 2 Leeson, P. D.; Iversen, L. L. J. Med. Chem. 1994, 37, 4053-4067.
5. 3 a) Kemp, J. A.; Leeson, P. D. Trends Pharmacol. Sci. 1993, 14, 20-25;
6. b) Koek, W.; Colpaert, F. C. In Multiple Sigma and PCP Receptor Ligands: Mechanism for Neuromodulation and Neuroprotection, Kamenka, J.-M.; Domino, E. F., Eds.; CPP Books: Ann Arbor, MI, 1992, pp. 665-671;
7. c) Singh, L.,; Menzies, R.; Tricklebank, M. D. Eur. J. Pharmacol. 1990, 186, 129-132;
8. d) Balster, R. L.; Grech, D. M.; Mansbach, R. S.; Li, H.; Weber, E. Soc. Neurosci. Abstr. 1993, 19,472,197.16.
9. 4 a) Ascher, P.; Johnson, J.W. In The NMDA Receptor, Collingridge, G.L.; Watkins, J.C. Ed.; Oxford University Press: New York, Second Ed. 1994, pp. 177-205;
10. b) Gill, R.; Hargraves, R. J.; Kemp, J. A. Cereb. Blood Flow. Metab. 1995, 15, 197-204.
11. 5 a) Kulagowski, J. J. Exp. Opin. Ther. Patents 1996, 6, 1069-1079;
12. b) Kulagowski, J. J.; Leeson, P. D. Exp. Opin. Ther. Patents 1995, 5, 1061-1075.
13. 6 Weber, E.; Keana, J. F. W., WO9400124 (1994).
14. 7 Zeneca Limited, WO9511244 (1995).
15. 8 Glaxo SPA, GB2266091 (1993).
16. 9 5-Aminomethylquinoxaline-2,3-diones, Parts I and II, Bioorg. Med. Chem. Lett.; in preparation.
17. 10 The preparation of the quinoxalines 5a-c is described in 5-Aminomethylquinoxaline-2,3-diones, Parts I and II, Bioorg. Med. Chem. Lett.; in preparation.
18. 11 Bayle-Lacoste, M.; Moulines, M.; Collignon, N.; Boumekouez, A.; de Tinguy-Moreaud, E.; Neuzil, E. Tetrahedron 1990, 46, 7793-7802.
19. 12 Honoré, T.; Lauridsen, J.; Krogsgaard-Larsen, P. J. Neurochem. 1982, 38, 173-178.
20. 13 Baron, B. M.; Siegel, B. W.; Harrison, B. L.; Gross, R. S.; Hawes, C.; Towers, P. J. Pharmacol. Exp. Ther. 1996, 279, 62-68.
21. 14 a) Schmutz, M.; Portet C.; Jeker, A.; Klebs, K.; Vassout, A.; Allgeier, H.; Heckendorn, R.; Fagg, G. E.; Olpe, H. R.; van Riezen H. Naunyn-Schmiedeberg's Arch. Pharmacol. 1990, 342, 61-66;
22. b) Wamil, A. W.; Schmutz, M.; Portet, C.; Feldmann, K. F.; McLean M. J. Eur. J. Pharmacol. 1994, 271, 301-308.
23. 15 Sauer, D.; Allegrini, P. R; Thedinga, K. H; Massieu L.; Amacker, H.; Fagg, G. E. J. Neurosci. Methods 1992, 42, 69-74.
24. 16 Zimmermann, K.; Schmutz, M.; Novartis Pharma 1996, unpublished results.